EV25 natural-influenza Phase 2 results
Eradivir dosed the first patient in a Bangladesh study of naturally occurring influenza in July 2026. EV25 recruits existing antibodies rather than directly inhibiting viral replication.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Do not confuse the new natural-infection study with Phase 2a challenge results already announced in 2025.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Bangladesh Phase 2 readout — date unconfirmed
Company context
Opened official company release. The About Eradivir section explicitly calls Eradivir Inc. a privately held clinical-stage biotech company. Positive company self-report dated April 15, 2026; refresh before market activation, not an independent October registry audit.
Potential outcome market
Will Eradivir publicly report the primary analysis of its Bangladesh EV25 natural-influenza Phase 2 study by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.